Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and Chloroquine Strategies for COVID-19
NCT04341727Phase 3Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxychloroquine and chloroquine in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Washington University School of Medicine. Primary endpoint: Hours to Recovery at 42 days. Started Apr 2020; status: terminated.
02
Drugs
hydroxychloroquinechloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04341727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341727.